Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.
作者信息
Levi Sarah R, Oh Jin Kyun, de Carvalho Jose Ronaldo Lima, Mahajan Vinit B, Tsang Stephen H, Sparrow Janet R
机构信息
Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York.
Department of Ophthalmology, Hospital das Clínicas de Pernambuco, Empresa Brasileira de Serviços Hospitalares, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
出版信息
JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.
Abstract
摘要
相似文献
1
Quantitative Autofluorescence Following Gene Therapy With Voretigene Neparvovec.使用voretigene neparvovec进行基因治疗后的定量自体荧光
JAMA Ophthalmol. 2020 Aug 1;138(8):919-921. doi: 10.1001/jamaophthalmol.2020.2018.
2
Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.Voretigene Neparvovec：治疗 RPE65 基因突变相关遗传性视网膜营养不良的综述。
Mol Diagn Ther. 2020 Aug;24(4):487-495. doi: 10.1007/s40291-020-00475-6.
3
Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.用于遗传性视网膜营养不良的voretigene neparvovec-rzyl（Luxturna）。
Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-55.
4
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.Voretigene Neparvovec-rzyl 在 RPE65 基因突变相关性遗传性视网膜营养不良中的疗效、安全性和持久性：1 期和 3 期试验结果。
Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22.
5
Bilateral Subretinal Voretigene Neparvovec-rzyl (Luxturna) Gene Therapy.双侧视网膜下注射维替泊芬基因治疗药物（Luxturna）基因疗法。
Ophthalmol Retina. 2019 May;3(5):450. doi: 10.1016/j.oret.2019.02.007.
6
Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.治疗对侧眼时使用不同病毒载体，后续接受雷珠单抗治疗后出现黄斑旁萎缩。
Transl Vis Sci Technol. 2024 Jun 3;13(6):11. doi: 10.1167/tvst.13.6.11.
7
Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl.经 voretigene neparvovec-rzyl 基因增强疗法治疗后，RPE65 相关视网膜营养不良患者全视野视网膜电图得到部分挽救。
Doc Ophthalmol. 2024 Oct;149(2):63-75. doi: 10.1007/s10633-024-09987-6. Epub 2024 Aug 14.
8
Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.雷柏氏先天性黑蒙 2 型患者经脉络膜视网膜下注射 voretigene neparvovec-rzyl 后出现旁中心凹脉络膜视网膜萎缩
Ophthalmol Retina. 2022 Jan;6(1):58-64. doi: 10.1016/j.oret.2021.03.016. Epub 2021 Apr 8.
9
Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.评估 Voretigene Neparvovec 治疗效果的客观结局。
Ophthalmol Retina. 2024 Jul;8(7):688-698. doi: 10.1016/j.oret.2024.01.021. Epub 2024 Feb 1.
10
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.临床视角：治疗 RPE65 相关的视网膜营养不良。
Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3.
引用本文的文献
1
Fundus Autofluorescence in Inherited Retinal Disease: A Review.遗传性视网膜疾病中的眼底自发荧光：综述
Cells. 2025 Jul 16;14(14):1092. doi: 10.3390/cells14141092.
2
Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice.用于 RPE65 突变引起的遗传性视网膜营养不良的 voretigene neparvovec：从临床试验到实际实践的资格和治疗挑战的范围审查。
Eye (Lond). 2024 Sep;38(13):2504-2515. doi: 10.1038/s41433-024-03065-6. Epub 2024 Apr 16.
3
Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic -Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center.单一中心队列患者双等位基因介导遗传性视网膜营养不良接受 voretigene neparvovec 治疗的结局和不良反应。
Biomolecules. 2023 Oct 5;13(10):1484. doi: 10.3390/biom13101484.
4
Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.脉络膜视网膜萎缩，尽管眼底自发荧光存在，但仍采用 voretigene neparvovec 治疗。
Mol Genet Genomic Med. 2022 Nov;10(11):e2038. doi: 10.1002/mgg3.2038. Epub 2022 Oct 12.
5
A novel phenotype in a family with autosomal dominant retinal dystrophy due to c.1430A > G in retinoid isomerohydrolase (RPE65) and c.37C > T in bestrophin 1 (BEST1).一个家族性常染色体显性视网膜营养不良的新表型，该疾病是由视黄醇异构酶（RPE65）中的 c.1430A>G 和 Bestrophin 1（BEST1）中的 c.37C>T 引起的。
Doc Ophthalmol. 2021 Aug;143(1):61-73. doi: 10.1007/s10633-021-09819-x. Epub 2021 Jan 29.
6
Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.临床视角：治疗 RPE65 相关的视网膜营养不良。
Mol Ther. 2021 Feb 3;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029. Epub 2020 Dec 3.
本文引用的文献
1
Lessons learned from quantitative fundus autofluorescence.从定量眼底自发荧光中吸取的教训。
Prog Retin Eye Res. 2020 Jan;74:100774. doi: 10.1016/j.preteyeres.2019.100774. Epub 2019 Aug 28.
2
Sustained Rescue of Rod Function and Probable Non-Cell-Autonomous Rescue of Cones after Gene Therapy.基因治疗后视杆细胞功能的持续挽救及视锥细胞可能的非细胞自主性挽救。
Ophthalmology. 2019 Sep;126(9):1286-1287. doi: 10.1016/j.ophtha.2019.03.007.
3
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.Voretigene Neparvovec-rzyl 在 RPE65 基因突变相关性遗传性视网膜营养不良中的疗效、安全性和持久性：1 期和 3 期试验结果。
Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22.
4
Safety and efficacy of gene transfer for Leber's congenital amaurosis.基因转移治疗莱伯先天性黑蒙的安全性和有效性。
N Engl J Med. 2008 May 22;358(21):2240-8. doi: 10.1056/NEJMoa0802315. Epub 2008 Apr 27.
5
Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65.患有与RPE65基因突变相关的早发性严重视网膜营养不良的患者自儿童期起缺乏对488纳米的眼底自发荧光。
Ophthalmology. 2004 Aug;111(8):1585-94. doi: 10.1016/j.ophtha.2004.01.033.
6
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle.Rpe65对于视网膜视觉循环中11-顺式视黄醛的产生是必需的。
Nat Genet. 1998 Dec;20(4):344-51. doi: 10.1038/3813.
Zotero 插件